李氏大药厂(00950)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

00950 李氏大药厂

已收盘 09-30 16:05:00

1.200

+0.030

+2.56%

最高1.205	最低1.160	成交量61.05万
今开1.165	昨收1.170	日振幅3.85%
总市值7.07亿	流通市值7.07亿	总股本5.89亿
成交额71.98万	换手率0.10%	流通股本5.89亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"00950","market":"HK","secType":"STK","nameCN":"李氏大药厂","latestPrice":1.2,"timestamp":1790755500058,"preClose":1.17,"halted":0,"volume":610500,"delay":0,"changeRate":0.025641025641025664,"floatShares":588835343,"shares":589000000,"eps":0.1561,"marketStatus":"已收盘","change":0.03,"latestTime":"09-30 16:05:00","open":1.165,"high":1.205,"low":1.16,"amount":719837,"amplitude":0.038462,"askPrice":1.205,"askSize":8000,"bidPrice":1.18,"bidSize":5000,"shortable":0,"etf":0,"ttmEps":0.203306,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1790904600000},"marketStatusCode":5,"adr":0,"listingDate":1026662400000,"exchange":"SEHK","adjPreClose":1.17,"dividendRate":0.048333,"openAndCloseTimeList":[[1790731800000,1790740800000],[1790744400000,1790755200000]],"volumeRatio":2.26542,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/00950","defaultTab":"news","newsList":[{"id":"2669246722","title":"董事总经理李烨妮增持李氏大药厂(00950.HK)20.6万股 每股作价1.15港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2669246722","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669246722?lang=zh_cn&edition=full","pubTime":"2026-09-24 19:24","pubTimestamp":1790249060,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["06622","BK1583","BK1574","BK1587","BK1191","00950"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1199360647","title":"李氏大药厂2026年上半年营收7.97亿元，经调整净利润0.95亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=1199360647","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1199360647?lang=zh_cn&edition=full","pubTime":"2026-09-23 07:06","pubTimestamp":1790118415,"startTime":"0","endTime":"0","summary":"2026年上半年，李氏大药厂实现营收约7.97亿元，同比增长14.6%。经调整净利润约0.95亿元，较去年同期0.67亿元增长41.4%。毛利率为56.2%，比上年同期上升4.4个百分点。经营活动产生的现金流约2.35亿元，而去年同期为1.84亿元，增幅达到27.3%。报告期内，公司销售及分销费用为1.80亿元，同比增长18.3%；行政费用达1.86亿元，同比增长83.2%。研发投入方面，公司合计产生约2.04亿元，同比增长28%，其中1.53亿元计入当期费用，占营收比重从上年同期的6.0%提升至19.2%。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"李氏大药厂2026年上半年营收7.97亿元，经调整净利润0.95亿元","news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00950"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1156184693","title":"李氏大药厂 - 1Cbio将保留根据与FDA的IND申请协议所产生数据的使用权与访问权","url":"https://stock-news.laohu8.com/highlight/detail?id=1156184693","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1156184693?lang=zh_cn&edition=full","pubTime":"2026-09-09 22:39","pubTimestamp":1788964770,"startTime":"0","endTime":"0","summary":"李氏大药厂——1Cbio将保留其依据与美国食品药品监督管理局（FDA）所签协议而生成的数据的访问及使用权。这一权利涵盖履行新药临床试验申请（IND）过程中所产生的各类数据资料。协议框架下，相关数据的获取与利用权限得以明确界定，为后续监管沟通与申报流程提供了关键支撑。值得注意的是，此类安排不仅涉及技术层面的合规要求，亦牵涉到知识产权与商业机密的保护策略。鉴于生物医药领域研发周期长、投入大且监管严苛的特点，对数据权的清晰界定于合作双方而言均是风险管控的重要环节。由此，上述权利的保留将持续为1Cbio在推进IND申报进程中提供必要的灵活性，助其应对监管环境中的动态变化。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00950","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1169042852","title":"李氏大药厂达成合作：OC-3将在中国大陆等地用于治疗DNA修复突变癌症","url":"https://stock-news.laohu8.com/highlight/detail?id=1169042852","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1169042852?lang=zh_cn&edition=full","pubTime":"2026-09-09 22:37","pubTimestamp":1788964649,"startTime":"0","endTime":"0","summary":"李氏大药厂日前宣布一项重要协议。根据该协议，OC-3这一药物将被开发用于治疗携带DNA修复突变的癌症患者。这一开发计划覆盖中国大陆及其他地区，为相关癌症治疗领域带来新的可能。\n此项合作聚焦于精准医疗方向，针对具有特定基因特征的肿瘤类型。DNA修复机制的缺陷，往往与某些癌症的发生发展密切相关，这使得OC-3有望成为一种更具针对性的治疗选择。\n值得关注的是，该药的市场布局不仅限于中国大陆，还延伸至其他区域。这一战略性的安排，或许意味着相关治疗方法有望惠及更广泛的患者群体。\n协议的达成，标志着李氏大药厂在肿瘤治疗领域的又一重要布局。随着相关研发工作的推进，OC-3的临床应用前景值得期待。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","00950"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1146207836","title":"李氏大药厂（00950）获OC-3大中华及东南亚独家开发生产与商业化权","url":"https://stock-news.laohu8.com/highlight/detail?id=1146207836","media":"公告速递","labels":["corporation","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1146207836?lang=zh_cn&edition=full","pubTime":"2026-09-09 22:36","pubTimestamp":1788964578,"startTime":"0","endTime":"0","summary":"2026年9月9日，李氏大药厂控股有限公司公告，其全资子公司李氏大药厂（香港）有限公司已与美国生物科技公司1cBio, Inc. 签署独家许可协议，获取PARP1抑制剂OC-3在中国内地、香港、澳门、台湾及东南亚若干国家的开发、生产及商业化权利。根据协议，李氏香港将承担OC-3在上述地区取得监管批准所需的GLP安全性研究和生产活动，并负责药物供应生产安排。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00950"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1191933369","title":"李氏大药厂8月无新增发行或股份变动","url":"https://stock-news.laohu8.com/highlight/detail?id=1191933369","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1191933369?lang=zh_cn&edition=full","pubTime":"2026-09-02 18:12","pubTimestamp":1788343950,"startTime":"0","endTime":"0","summary":"李氏大药厂于2026年9月2日发布截至2026年8月31日的股份变动月报表。公告显示，公司于报告期末的注册股本为10亿股普通股，面值每股0.05港元，折合注册股本总额5000万港元，与上月保持一致。截至8月31日，公司已发行股份为588,835,343股，库藏股数量为0，合计已发行股份总数588,835,343股，均较上月无变化。上述期权在报告期内未发生行使或变动。整体来看，本月度公司股本结构未发生新增发行、股份购回或注销变动。本次公告由董事李小芳签署。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00950"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1120675824","title":"李氏大药厂2026年上半年营收7.97亿港元，经调整净利润0.95亿港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1120675824","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1120675824?lang=zh_cn&edition=full","pubTime":"2026-08-31 17:57","pubTimestamp":1788170256,"startTime":"0","endTime":"0","summary":"李氏大药厂公告显示，截至2026年6月30日止六个月，公司营收约7.97亿港元，同比增长14.6%。经调整净利润为0.95亿港元，同比增长41.4%。报告期内毛利达到4.47亿港元，同比增长24.3%，毛利率从上年同期的51.8%提升至56.2%。公司在心血管、女性健康、儿科、罕见病及皮肤科等主攻领域的研发投入约2.04亿港元，同比增长28.0%，其中1.53亿港元计入当期费用。公司经营活动产生的现金净额为2.35亿港元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"李氏大药厂2026年上半年营收7.97亿港元，经调整净利润0.95亿港元","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00950"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663071315","title":"李氏大药厂(00950)公布中期业绩 拥有人应占溢利9501.4万港元 同比增长41.4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2663071315","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663071315?lang=zh_cn&edition=full","pubTime":"2026-08-31 17:50","pubTimestamp":1788169857,"startTime":"0","endTime":"0","summary":"智通财经APP讯，李氏大药厂 公布2026年中期业绩，收益约7.97亿港元，同比增长14.6%;公司拥有人应占溢利9501.4万港元，同比增长41.4%;每股盈利16.14港仙，每股中期股息3.5港仙。其中，引进产品的收益增加24.3%至约3.37亿港元，主要源于《菲普利》、《布累迪宁》、《曲特恪》及《芮舒延》的贡献。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1489545.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1587","06622","BK1583","00950","BK1191","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662472467","title":"港股异动 | 李氏大药厂(00950.HK)盈喜后涨超20% 预计中期股东应占纯利约8500万至9500万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2662472467","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662472467?lang=zh_cn&edition=full","pubTime":"2026-08-27 10:34","pubTimestamp":1787798089,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["00950","BK1587","06622","BK1583","BK1191","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662126957","title":"李氏大药厂(00950)发盈喜 预计中期股东应占纯利约8500万至9500万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2662126957","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662126957?lang=zh_cn&edition=full","pubTime":"2026-08-26 21:21","pubTimestamp":1787750513,"startTime":"0","endTime":"0","summary":"智通财经APP讯，李氏大药厂(00950)发布公告，集团预期截至2026年6月30日止六个月将取得未经审核股东应占纯利介于约8500万港元至9500万港元，而截至2025年6月30日止六个月则取得约6720万港元。预期集团的中期业绩有所改善，主要源于(其中包括)(i)集团的收益增长;(ii)集团的整体毛利率改善，而此乃归因于产品组合更为理想，其中利润较高之专科及引进产品占比较大，以及集团各生产基地的制造效率持续提升。上述两项因素结合产生的正面影响，足以抵销报告期内所取得研究及开发费用、销售及分销费用以及行政费用(包括与集团新综合入账的美国业务相关的成本)增加。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1486422.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","BK1574","BK1587","06622","00950","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1134288273","title":"李氏大药厂（00950）发布正面盈利预告：预计2026年中期净利最高达9,500万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1134288273","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1134288273?lang=zh_cn&edition=full","pubTime":"2026-08-26 21:13","pubTimestamp":1787750002,"startTime":"0","endTime":"0","summary":"2026年8月26日，李氏大药厂控股有限公司在港交所公告，基于对集团截至2026年6月30日止六个月未经审核财务资料的初步评估，预计期内股东应占净利润将介乎约8,500万港元至9,500万港元，较2025年同期的约6,720万港元显著增长。公司表示，目前仍在编制截至2026年6月30日止六个月的中期业绩，相关未经审核综合管理账目尚未由核数师确认。依据上市规则要求，李氏大药厂计划于2026年8月31日公布正式的中期业绩报告。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00950"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1119031522","title":"李氏大药厂（00950）将于8月31日召开董事会 审议2026年中期业绩及分红议案","url":"https://stock-news.laohu8.com/highlight/detail?id=1119031522","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1119031522?lang=zh_cn&edition=full","pubTime":"2026-08-18 18:25","pubTimestamp":1787048733,"startTime":"0","endTime":"0","summary":"李氏大药厂（00950）8月18日公告称，公司董事会会议拟于2026年8月31日（星期一）在香港新界沙田香港科学园第三期科技大道东20E大楼1楼举行。会议主要议程包括：\n\n1. 审议并（如认为合适）批准刊发公司及其附属公司截至2026年6月30日止六个月的未经审核中期业绩；  \n2. 考虑建议派付中期股息（如有）。\n\n公告显示，李氏大药厂现有两位执行董事李小芳（主席）及李烨妮，其余董事包括三名非执行董事和三名独立非执行董事。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00950"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659119634","title":"港股异动 | 李氏大药厂(00950)涨超7% ZK2401于中国提交新药临床试验申请已获NMPA受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2659119634","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659119634?lang=zh_cn&edition=full","pubTime":"2026-08-14 15:36","pubTimestamp":1786692986,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，李氏大药厂涨超7%，截至发稿，涨7.27%，报1.18港元，成交额201.32万港元。消息面上，近期，李氏大药厂发布公告，本集团就ZK2401于中国的新药临床试验申请已获得中国国家药品监督管理局药品评审中心受理。ZK2401为李氏大药厂自主研发的专有抗体药物偶联物项目，由李氏大药厂拥有该分子的完整全球知识产权。作为李氏大药厂ADC平台的首个项目，ZK2401标志着本集团推进该平台发展的一个重要起点。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1479979.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["VXUS","00950","BK1587","IBBQ","KCAI","PSYK","06622","BK4585","BK1574","IBBJ","BMED","BK4588","MDTX","BK1583","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657667506","title":"李氏大药厂(00950.HK)转仓市值总计4607.25万港元 占比7.24% 从南洋商业银行转出4243.83万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2657667506","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657667506?lang=zh_cn&edition=full","pubTime":"2026-08-07 08:27","pubTimestamp":1786062441,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1560","BK1583","BK1587","BK1231","06622","BK1191","BK1574","09668","00950"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1114592390","title":"李氏大药厂7月无新增发行或股份变动","url":"https://stock-news.laohu8.com/highlight/detail?id=1114592390","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1114592390?lang=zh_cn&edition=full","pubTime":"2026-08-03 22:36","pubTimestamp":1785767768,"startTime":"0","endTime":"0","summary":"李氏大药厂于2026年8月3日发布截至2026年7月31日的证券变动月报表。公告显示，公司注册股本及已发行股本在报告期内保持稳定，未出现新增发行、股份购回或库存股出售等变动。根据公告，截至7月末，公司法定注册股本为10亿股普通股，每股面值为0.05港元，合计注册股本5,000万港元，较上月无变化；已发行股本维持在588,835,343股，库存股数量仍为0股。公司现有2012年及2022年通过采购股权计划所授出的股份期权分别为19,918,000股和4,778,000股，本月内未见行使或变动。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00950"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655059788","title":"李氏大药厂(00950.HK)：专有ADC项目ZK2401于中国提交新药临床试验申请获NMPA受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2655059788","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655059788?lang=zh_cn&edition=full","pubTime":"2026-07-30 22:13","pubTimestamp":1785420782,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["00950","06622","BK1574","BK1191","BK1583","BK1587"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1101281124","title":"李氏大药厂（00950）：自主ADC项目ZK2401临床试验申请获NMPA受理","url":"https://stock-news.laohu8.com/highlight/detail?id=1101281124","media":"公告速递","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1101281124?lang=zh_cn&edition=full","pubTime":"2026-07-30 22:11","pubTimestamp":1785420685,"startTime":"0","endTime":"0","summary":"2026年7月30日，李氏大药厂控股有限公司发布自愿性公告称，其自主研发的抗体药物偶联物项目ZK2401于2026年7月29日在中国提交的新药临床试验申请已获国家药品监督管理局药品审评中心受理。ZK2401基于公司自主研发的抗PD-L1抗体索卡佐利单抗，并偶联新型拓扑异构酶I抑制剂载荷。根据现行审评路径，ZK2401的审评周期预计约30个工作天，公司预计最早可于2026年9月获得临床试验批准，并于2026年10月开始入组首名患者。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00950"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1145304953","title":"艾士林制药签署协议，获得特定药品独家开发与商业化权利","url":"https://stock-news.laohu8.com/highlight/detail?id=1145304953","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1145304953?lang=zh_cn&edition=full","pubTime":"2026-07-21 19:03","pubTimestamp":1784631821,"startTime":"0","endTime":"0","summary":"艾士林制药公司近日宣布，已成功签署一项重要协议，从而获得了特定药物产品在全球范围内的独家开发与商业化权利。此举标志着该公司在拓展其产品管线与强化市场竞争力方面迈出了关键一步。\n根据协议条款，艾士林将全权负责这些药物的后续研发、临床试验推进以及最终的上市推广。此项合作有望为公司在未来数年内带来新的增长动力，并巩固其在相关治疗领域的战略布局。公司管理层表示，该协议符合其长期发展战略，旨在通过引入创新疗法来满足未竟的医疗需求。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00950","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652028501","title":"李氏大药厂(00950)就干扰素ALPHA-2B产品与ASHLINS订立大中华地区以外独家许可及供应协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2652028501","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2652028501?lang=zh_cn&edition=full","pubTime":"2026-07-17 21:36","pubTimestamp":1784295413,"startTime":"0","endTime":"0","summary":"智通财经APP讯，李氏大药厂 发布公告，于2026年7月6日，公司与Ashlins Ocular Pharmaceuticals, Inc. 订立独家许可协议。根据该协议，公司同意向Ashlins许可及供应干扰素Alpha-2b，以供其于中国内地、香港、澳门及台湾以外所有地区开发及商业化用于诊断、预防或治疗若干人类疾病的药品。干扰素Alpha-2b乃一种透过重组DNA技术生产的重组人I型干扰素活性药物成分，用作具有抗病毒及免疫调节活性的药品的活性物质。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1469289.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1587","00950","06622","BK1574","BK1583","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136516681","title":"李氏大药厂（00950）签署干扰素Alpha-2b大中华区以外独家许可及供应协议","url":"https://stock-news.laohu8.com/highlight/detail?id=1136516681","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1136516681?lang=zh_cn&edition=full","pubTime":"2026-07-17 21:35","pubTimestamp":1784295331,"startTime":"0","endTime":"0","summary":"2026年7月17日，李氏大药厂控股有限公司发布自愿性公告称，公司已于2026年7月6日与美国生物医药公司Ashlins Ocular Pharmaceuticals, Inc.订立独家许可协议。根据协议，李氏大药厂将向Ashlins许可并供应干扰素Alpha-2b，用于在中国内地、香港、澳门及台湾以外地区开发及商业化针对若干人类疾病的药品。干扰素Alpha-2b是一种通过重组DNA技术生产的重组人I型干扰素活性药物成分，具有抗病毒及免疫调节活性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00950"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.leespharm.com","stockEarnings":[{"period":"1week","weight":-0.0051},{"period":"1month","weight":-0.1014},{"period":"3month","weight":0.1688},{"period":"6month","weight":0.0174},{"period":"1year","weight":-0.4626},{"period":"ytd","weight":-0.1903}],"compareEarnings":[{"period":"1week","weight":-0.0225},{"period":"1month","weight":-0.0415},{"period":"3month","weight":0.0718},{"period":"6month","weight":-0.0236},{"period":"1year","weight":-0.0789},{"period":"ytd","weight":-0.0432}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"李氏大药厂控股有限公司是一家主要从事药品开发、制造、市场推广及销售业务的投资控股公司。该公司通过两个分部运营业务。引进产品分部买卖引进的产品。其引进产品包括可益能注射液、菲普利口服溶液等。专利产品分部制造及销售自行研发的产品。其研发产品包括锐思力药片、ADASUVE吸入粉雾剂等。该公司药品覆盖心血管及传染疾病、皮肤医学、肿瘤学、妇科学及眼科学等领域。该公司主要在中国大陆、香港、台湾开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.5625,"avgChangeRate":0.049698},{"month":2,"riseRate":0.375,"avgChangeRate":-0.022896},{"month":3,"riseRate":0.4375,"avgChangeRate":-0.02913},{"month":4,"riseRate":0.4375,"avgChangeRate":-0.000887},{"month":5,"riseRate":0.625,"avgChangeRate":0.036917},{"month":6,"riseRate":0.352941,"avgChangeRate":-0.025863},{"month":7,"riseRate":0.529412,"avgChangeRate":0.026552},{"month":8,"riseRate":0.411765,"avgChangeRate":-0.023892},{"month":9,"riseRate":0.411765,"avgChangeRate":0.011489},{"month":10,"riseRate":0.4375,"avgChangeRate":-0.006899},{"month":11,"riseRate":0.5625,"avgChangeRate":0.012753},{"month":12,"riseRate":0.4375,"avgChangeRate":0.016874}],"exchange":"SEHK","name":"李氏大药厂","nameEN":"LEE'S PHARM"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"李氏大药厂(00950)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供李氏大药厂(00950)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"李氏大药厂,00950,李氏大药厂股票,李氏大药厂股票老虎,李氏大药厂股票老虎国际,李氏大药厂行情,李氏大药厂股票行情,李氏大药厂股价,李氏大药厂股市,李氏大药厂股票价格,李氏大药厂股票交易,李氏大药厂股票购买,李氏大药厂股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"李氏大药厂(00950)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供李氏大药厂(00950)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}